Australia's most trusted
source of pharma news
Posted 22 December 2025 PM
Psoriasis patients may soon be able to enjoy clear skin by taking a daily pill, after Takeda reported promising results for its investigational psoriasis medicine zasocitinib (TAK-279) in two phase 3 trials.
By week 16 more than half the study participants (adults with moderate to severe plaque psoriasis) taking zasocitinib once daily achieved clear or almost clear skin, (Psoriasis Area and Severity Index 90). On average about 30 per cent achieved completely clear skin (PASI 100).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.